Astellas Pharma Inc
TSE:4503
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2), the stock would be worth ¥1 955.23 (21% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.5 | ¥2 468 |
0%
|
| 3-Year Average | 2 | ¥1 955.23 |
-21%
|
| 5-Year Average | 2.2 | ¥2 138.63 |
-13%
|
| Industry Average | 1.6 | ¥1 563.1 |
-37%
|
| Country Average | 1.4 | ¥1 390.86 |
-44%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Astellas Pharma Inc
TSE:4503
|
4.4T JPY | 2.5 | 13.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 31.5 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 5.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 1.8 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 6.4 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.4 |
| 70th Percentile | 2.1 |
| Max | 31 732 017.6 |
Other Multiples
Astellas Pharma Inc
Glance View
Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.
